2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
December 15, 2014
Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors
December 9, 2014
Aptose Biosciences Presents APTO 253 Preclinical Data at 56th American Society of Hematology Annual Meeting
December 5, 2014
Aptose Biosciences to Present at Oppenheimer Co 25th Annual Healthcare Conference
December 3, 2014
Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting
November 17, 2014
Aptose Biosciences to Present at The Stifel 2014 Healthcare Conference
November 4, 2014
Aptose Biosciences reports results for the four months ended September 30, 2014
October 30, 2014
Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014
October 21, 2014
Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO
October 3, 2014
Aptose Biosciences to Present at the 2014 BIO Investor Forum
October 1, 2014
Aptose Biosciences Announces Reverse Stock Split
September 29, 2014
Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative with Oregon Health & Science University
September 25, 2014
Aptose Biosciences to Present at Upcoming Investor Conferences
September 8, 2014
Aptose Biosciences Recruits Stephen B. Howell, M.D. to Act in the Capacity of Chief Medical Officer
September 2, 2014
Lorus Therapeutics Implements Name Change to Aptose Biosciences
August 19, 2014
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
August 7, 2014
Lorus Therapeutics to Present at the Canaccord Genuity 34th Annual Growth Conference
July 28, 2014
Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers
July 15, 2014
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing
July 15, 2014
Lorus Therapeutics Reports Results for the Fourth Quarter and Full Year Ended May 31, 2014
July 10, 2014
Lorus Therapeutics To Host Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
June 19, 2014
Lorus Therapeutics to Present at the 9th JMP Securities Healthcare Conference
June 16, 2014
Lorus Therapeutics to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
June 10, 2014
Lorus Therapeutics Provides Update on Warrants
April 22, 2014
Lorus Therapeutics Inc. Announces Exercise of Over-Allotment Option in Connection with Public Offering of Common Shares
April 10, 2014
Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014
April 10, 2014
Lorus Therapeutics Inc. Completes $25 Million Offering of Common Shares
April 8, 2014
Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast
April 8, 2014
TORONTO, ONTARIO--(April 10, 2014) - Lorus Therapeutics Inc. (TSX:LOR) (Lorus") reported financial results for the three and nine months ended February 28, 2014 and provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.
April 4, 2014
Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014
March 27, 2014
Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to $25M
March 27, 2014
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
March 26, 2014
Lorus Therapeutics Inc. Announces $17M Overnight Marketed Financing
March 18, 2014
Lorus Therapeutics Announces the Departure of Its President and Chief Operating Officer
March 5, 2014
Lorus Therapeutics to Present at the 26th Annual ROTH Conference
February 24, 2014
Lorus Therapeutics to Present at the RBC Capital Markets 2014 Global Healthcare Conference
January 13, 2014
Lorus Therapeutics to Present at Biotech Showcase™ 2014
January 8, 2014
Lorus Therapeutics Inc. Announces Exercise in Full of Over-Allotment Option in Connection With Public Offering of Common Shares
January 7, 2014
Lorus Therapeutics Reports Second Quarter Results for Fiscal 2014